Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?

Key Points

• Oramed Pharmaceuticals' stock price fell below its 200-day moving average of $2.20, trading as low as $2.17 before closing at $2.23.
• Wall Street Zen downgraded the stock from a "hold" rating to a "sell" rating, which may signal caution for investors.
• The company reported a loss of $0.05 EPS for the last quarter, missing the consensus estimate of ($0.04) by $0.01.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.20 and traded as low as $2.17. Oramed Pharmaceuticals shares last traded at $2.23, with a volume of 58,883 shares traded.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen downgraded Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. One analyst has rated the stock with a Hold rating, According to MarketBeat, the company has a consensus rating of "Hold".

Oramed Pharmaceuticals Trading Up 0.5%

The firm has a 50 day moving average of $2.14 and a 200-day moving average of $2.20. The company has a market cap of $91.43 million, a P/E ratio of -6.37 and a beta of 1.69.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last issued its earnings results on Thursday, August 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Equities analysts predict that Oramed Pharmaceuticals Inc. will post -0.03 EPS for the current fiscal year.

Institutional Trading of Oramed Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BML Capital Management LLC raised its stake in Oramed Pharmaceuticals by 2.1% during the 2nd quarter. BML Capital Management LLC now owns 3,083,253 shares of the biotechnology company's stock valued at $6,937,000 after purchasing an additional 62,505 shares during the period. Peapod Lane Capital LLC raised its stake in Oramed Pharmaceuticals by 11.0% during the 1st quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock valued at $540,000 after purchasing an additional 24,985 shares during the period. Dimensional Fund Advisors LP raised its stake in Oramed Pharmaceuticals by 143.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 70,190 shares during the period. Jane Street Group LLC raised its stake in Oramed Pharmaceuticals by 35.3% during the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock valued at $144,000 after purchasing an additional 17,510 shares during the period. Finally, N.E.W. Advisory Services LLC raised its stake in Oramed Pharmaceuticals by 52.9% during the 1st quarter. N.E.W. Advisory Services LLC now owns 18,900 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 6,540 shares during the period. Institutional investors own 12.73% of the company's stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.